Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Factors Influencing Prescription Drug Costs in the United States

Factors Influencing Prescription Drug Costs in the United States Letters Table. Estimated Hazard Ratios for Time to Death or Heart Failure Rehospitalization Through 180 Days No. of Patients P Value for Subgroup Value, Mean (SD) Liraglutide Placebo HR (95% CI) P Value Interaction LVEF, % ≤Median 16.5 (4.4) 79 73 0.97 (0.59-1.60) .92 >Median 28.7 (4.8) 75 73 1.73 (1.06-2.84) .03 BMI <Median 25.9 (3.5) 80 69 1.11 (0.68-1.82) .67 ≥Median 39.1 (6.7) 73 76 1.53 (0.94-2.50) .09 Abbreviations: BMI, body mass index; HR, hazard ratio; LVEF, left ventricular Hazard ratios <1.0 favor liraglutide. ejection fraction. b Calculated as weight in kilograms divided by height in meters squared. Within the FIGHT study population, Carbone and colleagues Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Margulies inquire about how quantitative differences in LVEF affected re- reported receiving grants from Juventis Therapeutics, Celladon, Thoratec, sponses to liraglutide within the larger population of patients Innolign Biomedical, and Merck Sharp and Dohme; and serving as a consultant with advanced heart failure and reduced LVEF. In the requested for Janssen, Merck Sharp and Dohme, Pfizer, and Ridgetop Research. Dr Cappola reported receiving personal fees from Novartis and Teva. No other http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Factors Influencing Prescription Drug Costs in the United States

JAMA , Volume 316 (22) – Dec 13, 2016

Loading next page...
 
/lp/american-medical-association/factors-influencing-prescription-drug-costs-in-the-united-states-4uYP92xLHO
Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2016.17293
pmid
27959991
Publisher site
See Article on Publisher Site

Abstract

Letters Table. Estimated Hazard Ratios for Time to Death or Heart Failure Rehospitalization Through 180 Days No. of Patients P Value for Subgroup Value, Mean (SD) Liraglutide Placebo HR (95% CI) P Value Interaction LVEF, % ≤Median 16.5 (4.4) 79 73 0.97 (0.59-1.60) .92 >Median 28.7 (4.8) 75 73 1.73 (1.06-2.84) .03 BMI <Median 25.9 (3.5) 80 69 1.11 (0.68-1.82) .67 ≥Median 39.1 (6.7) 73 76 1.53 (0.94-2.50) .09 Abbreviations: BMI, body mass index; HR, hazard ratio; LVEF, left ventricular Hazard ratios <1.0 favor liraglutide. ejection fraction. b Calculated as weight in kilograms divided by height in meters squared. Within the FIGHT study population, Carbone and colleagues Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Margulies inquire about how quantitative differences in LVEF affected re- reported receiving grants from Juventis Therapeutics, Celladon, Thoratec, sponses to liraglutide within the larger population of patients Innolign Biomedical, and Merck Sharp and Dohme; and serving as a consultant with advanced heart failure and reduced LVEF. In the requested for Janssen, Merck Sharp and Dohme, Pfizer, and Ridgetop Research. Dr Cappola reported receiving personal fees from Novartis and Teva. No other

Journal

JAMAAmerican Medical Association

Published: Dec 13, 2016

References